Corresponding Author: Salman Razvi, MD, Translational and Clinical Research Institute, Newcastle University, Gateshead Health NHS Foundation Trust, Newcastle upon Tyne NE1 3BZ, United Kingdom (firstname.lastname@example.org).
Accepted for Publication: May 15, 2020.
Author Contributions: Dr Razvi had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Junejo, Pearce, Zaman, Razvi.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Jabbar, Hollingsworth, Razvi.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Jabbar, Stocken, Razvi.
Obtained funding: Pearce, Razvi.
Administrative, technical, or material support: Ingoe, Junejo, Parikh, Austin, Hollingsworth, Pearce, Greenwood, Zaman.
Supervision: Jabbar, Junejo, Carey, Parikh, Hollingsworth, Stocken, Pearce, Greenwood, Zaman, Razvi.
Conflict of Interest Disclosures: Dr Austin reported receiving personal fees from Abbott Vascular and AstraZeneca and grants from TA Sciences outside the submitted work. Dr Hollingsworth reported receiving a Medical Research Council New Investigator Research Grant (G1100160, 2012-2015) during the conduct of the study. Dr Pearce reported receiving personal fees from Quidel, Sanofi, and Berlin Chemie and nonfinancial support from Apitope BV outside the submitted work. Dr Razvi reported receiving grants from the National Institute for Health Research (NIHR) and nonfinancial support from Amdipharm Pharmaceuticals UK Ltd during the conduct of the study and personal fees from Merck Plc and Abbott Pharmaceuticals Pvt Ltd outside the submitted work. No other disclosures were reported.
Funding/Support: Dr Razvi was funded by an NIHR Career Development Fellowship (CDF-2012-05-231). The research was supported in part by the NIHR infrastructure at the University of Leeds.
Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Disclaimer: The views expressed in this publication are those of the author(s) and not necessarily those of the National Health Service, the NIHR, or the Department of Health and Social Care. Levothyroxine was provided free of cost by Amdipharm Pharmaceuticals UK Ltd.
Data Sharing Statement: See Supplement 4.
Additional Contributions: Independent trial steering committee: Janis Hickey (chair), Akheel Syed (independent member). Independent data and safety monitoring committee: Colin Dayan (chair), Steff Lewis (statistician), Rajiv Das (magnetic resonance [MR] expert). Tim Hodgson, MClinSci (senior research radiographer), Louise Ward, DCR(R) (radiographer), Dorothy Wallace, MClinSci (radiographer) (Newcastle MR Centre, Newcastle University); Petra Bijsterveld, MA (senior research nurse and MR manager) (University of Leeds); Thomas Chadwick, PhD (clinical trials statistician) (Population Health Sciences Institute, Newcastle University); James Wason, PhD (professor of biostatistics) (Newcastle University); Yan Hunter Blair (Newcastle Pharmacy Production Unit, Newcastle upon Tyne Hospitals); and Ruth Wood (randomization software) and Lee Munro, BSc (trial manager) (Newcastle Clinical Trials Unit, Newcastle University). None of the individuals named above received compensation for their role in the study.
K , Wallentin
L , Lindhagen
et al. Improved outcomes in patients with ST-elevation myocardial infarction during the last 20 years are related to implementation of evidence-based treatments: experiences from the SWEDEHEART registry 1995-2014. Eur Heart J
. 2017;38(41):3056-3065. doi:10.1093/eurheartj/ehx515PubMedGoogle ScholarCrossref
G , Igland
J , Vollset
et al. Heart failure complicatng acute myocardial infarction; burden and timing of occurrence: a nation-wide analysis including 86771 patients from the cardiovascular disease in Norway (CVDNOR) project. J Am Heart Assoc
. 2016;5(1):e002667. doi:10.1161/JAHA.115.002667PubMedGoogle Scholar
SM , Koh
YS , Park
et al. Thyroid stimulating hormone elevation as a predictor of long-term mortality in patients with acute myocardial infarction. Clin Cardiol
. 2018;41(10):1367-1373. doi:10.1002/clc.23062PubMedGoogle ScholarCrossref
National Institute for Health and Care Excellence. Thyroid disease: assessment and management: NICE guideline [NG145]. Published November 20, 2019. Accessed March 30, 2020. https://www.nice.org.uk/guidance/ng145
A , Ingoe
L , Pearce
S , Zaman
A , Razvi
S . Thyroxine in acute myocardial infarction (ThyrAMI): levothyroxine in subclinical hypothyroidism post-acute myocardial infarction: study protocol for a randomised controlled trial. Trials
. 2015;16:115. doi:10.1186/s13063-015-0621-5PubMedGoogle ScholarCrossref
JG , Staehling
NW , Flanders
et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab
. 2002;87(2):489-499. doi:10.1210/jcem.87.2.8182PubMedGoogle ScholarCrossref
B , Ware
JE , Aaronson
et al. Cross-validation of item selection and scoring for the SF-12 Health Survey in nine countries: results from the IQOLA Project: international quality of life assessment. J Clin Epidemiol
. 1998;51(11):1171-1178. doi:10.1016/S0895-4356(98)00109-7PubMedGoogle ScholarCrossref
PM , Seeley
JR , Roberts
RE , Allen
NB . Center for Epidemiologic Studies Depression Scale (CES-D) as a screening instrument for depression among community-residing older adults. Psychol Aging
. 1997;12(2):277-287. doi:10.1037/0882-7922.214.171.1247PubMedGoogle ScholarCrossref
RN , Whalley
GA , Walsh
HA , Gamble
GD , López-Sendón
J , Sharpe
N ; CAPRICORN Echo Substudy Investigators. Effects of carvedilol on left ventricular remodeling after acute myocardial infarction: the CAPRICORN Echo Substudy. Circulation
. 2004;109(2):201-206. doi:10.1161/01.CIR.0000108928.25690.94PubMedGoogle ScholarCrossref
LM , Ingkanisorn
WP , Rhoads
KL , Agyeman
KO , Arai
AE . Qualitative assessment of regional left ventricular function can predict MRI or radionuclide ejection fraction: an objective alternative to eyeball estimates. J Cardiovasc Magn Reson
. 2003;5(3):451-463. doi:10.1081/JCMR-120022261PubMedGoogle ScholarCrossref
F , Di Bello
V , Caraccio
et al. Effect of levothyroxine on cardiac function and structure in subclinical hypothyroidism: a double blind, placebo-controlled study. J Clin Endocrinol Metab
. 2001;86(3):1110-1115. doi:10.1210/jcem.86.3.7291PubMedGoogle ScholarCrossref
S , Leng
O , Jabbar
et al. Sample timing, diagnosis of subclinical thyroid dysfunction and mortality in acute myocardial infarction: ThyrAMI1 study. J Clin Endocrinol Metab
. 2020;105(4):dgz143. doi:10.1210/clinem/dgz143PubMedGoogle Scholar
S , Ingoe
L , Keeka
G , Oates
C , McMillan
C , Weaver
JU . The beneficial effect of L-thyroxine on cardiovascular risk factors, endothelial function, and quality of life in subclinical hypothyroidism: randomized, crossover trial. J Clin Endocrinol Metab
. 2007;92(5):1715-1723. doi:10.1210/jc.2006-1869PubMedGoogle ScholarCrossref
F , Caraccio
N , Kozàkowà
et al. Effect of levothyroxine replacement on lipid profile and intima-media thickness in subclinical hypothyroidism: a double-blind, placebo- controlled study. J Clin Endocrinol Metab
. 2004;89(5):2099-2106. doi:10.1210/jc.2003-031669PubMedGoogle ScholarCrossref
EL , Marassi
MP , Fortunato
et al. Thyroid function disturbance and type 3 iodothyronine deiodinase induction after myocardial infarction in rats a time course study. Endocrinology
. 2007;148(10):4786-4792. doi:10.1210/en.2007-0043PubMedGoogle ScholarCrossref
A , Mastorci
F , Piaggi
et al. Usefulness of triiodothyronine replacement therapy in patients with ST elevation myocardial infarction and borderline/reduced triiodothyronine levels (from the THIRST Study). Am J Cardiol
. 2019;123(6):905-912. doi:10.1016/j.amjcard.2018.12.020PubMedGoogle ScholarCrossref